SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System
Sign Up to like & getrecommendations! Published in 2017 at "Diabetologia"
DOI: 10.1007/s00125-017-4301-8
Abstract: Aims/hypothesisSodium-glucose co-transporter-2 inhibitors (SGLT2i) are indicated for the treatment of type 2 diabetes and may also improve glucose control in type 1 diabetes. In 2015, regulatory agencies warned that SGLT2i may favour diabetic ketoacidosis (DKA).… read more here.
Keywords: dka; reporting; dka reports; reports sglt2i ... See more keywords